20:10 , Mar 1, 2019 |  BC Week In Review  |  Company News

In latest deal, AbbVie and Voyager seek vectorized antibodies for Parkinson's

AbbVie Inc. (NYSE:ABBV) is expanding its gene therapy footprint through a deal with Voyager Therapeutics Inc. (NASDAQ:VYGR) to develop vectorized antibodies that can cross the blood-brain barrier to target α-synuclein to treat Parkinson's disease. Voyager...
21:06 , Feb 28, 2019 |  BC Innovations  |  Tools & Techniques

Synuclein PET project

As the Parkinson’s field starts to solve the problem of how to detect toxic α-synuclein in the brain, it’s closing in on imaging agents that could de-risk clinical trials. Phase I data expected this year...
00:14 , Feb 23, 2019 |  BC Extra  |  Company News

In latest deal, AbbVie and Voyager seek vectorized antibodies for Parkinson's

AbbVie Inc. (NYSE:ABBV) is expanding its gene therapy footprint through a deal with Voyager Therapeutics Inc. (NASDAQ:VYGR) to develop vectorized antibodies that can cross the blood-brain barrier to target α-synuclein to treat Parkinson's disease. Voyager...
19:03 , Jan 24, 2019 |  BC Innovations  |  Tools & Techniques

Mapping symptoms to brain circuits

Harvard physician scientist Michael Fox is using brain imaging to map neurological symptoms to the circuits that drive them, and thinks his connectivity maps can yield opportunities for drug developers. Fox, an associate professor of...
17:51 , Dec 20, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Parkinson's disease (PD) Cell culture and mouse studies suggest PARP inhibitors could help treat PD. In primary mouse cortical neurons cultured with α-synuclein fibrils, the PARP inhibitors veliparib, Rubraca rucaparib and Talzenna talazoparib decreased...
21:59 , Dec 6, 2018 |  BC Week In Review  |  Clinical News

Yumanity reveals Parkinson's candidate as first compound from yeast platform

Yumanity Therapeutics LLC (Cambridge, Mass.) and colleagues used the company's yeast platform to identify inhibitors of the enzyme stearoyl-CoA desaturase-1 (SCD1) that could prevent α-synuclein toxicity in Parkinson's disease. The SCD1 inhibitors are the first...
17:44 , Nov 16, 2018 |  BC Week In Review  |  Company News

AbbVie strengthens early stage neurology focus with Mission deal

Mission Therapeutics Ltd. (Cambridge, U.K.) and AbbVie Inc. (NYSE:ABBV) partnered to develop deubiquitinase inhibitors for Alzheimer's and Parkinson's diseases. The deal is the second in as many weeks for AbbVie for early stage neurology candidates....
18:45 , Nov 9, 2018 |  BC Week In Review  |  Company News

AbbVie gains Parkinson’s pipeline from BioArctic

AbbVie Inc. (NYSE:ABBV) gained exclusive, worldwide rights to a pipeline of antibodies targeting α-synuclein (SNCA) to treat Parkinson’s disease for $50 million through an option exercise with BioArctic AB (SSE:BIOA B). The deal is valued...
18:26 , Nov 7, 2018 |  BioCentury  |  Emerging Company Profile

ABL bispecifics

Korean biotech ABL Bio Inc. is developing bispecifics for cancer and Parkinson’s disease, and has evidence suggesting its lead candidate against VEGF and DLL4 is more potent than at least one of its Western competitors....
20:46 , Nov 6, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Parkinson’s disease Patient sample, mouse and rat studies identified an NLRP3 inhibitor that could help treat PD. In patient postmortem brain tissue samples, levels of NLRP3 in the substantia nigra were higher than in...